Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy

Prognosis from pancreatic ductal adenocarcinoma (PDAC) continues to be poor despite the many efforts channeled to improve its management. Although the mainstay treatment is still traditional chemotherapy, recent advances highlighted a promising potential for targeted therapy in the management of this disease. Those advances emphasize the significance of timely genomic profiling of tumor tissue as well as germline testing of patients to identify potential markers of targeted therapy. While targeted therapy is reserved for a relatively small subset of patients with PDAC, ongoing research is uncovering additional markers, and targeted agents, that will hopefully translate to better outcomes for patients.

Automated summary

Despite poor prognosis of pancreatic ductal adenocarcinoma (PDAC), recent advances in targeted therapy show promising potential for better outcomes. Timely genomic profiling and germline testing are crucial for identifying markers suitable for targeted therapy, offering hope for improved management of the disease.